ERCC1 Targeted Trial

PHASE3TerminatedINTERVENTIONAL
Enrollment

648

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

July 31, 2013

Conditions
Lung Cancer
Interventions
DRUG

Cisplatin, Paclitaxel

"* Cisplatin 75mg/m2, Day 1~* Paclitaxel 175mg/m2, Day 1"

Trial Locations (1)

Unknown

University College London Hospitals, London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Eli Lilly and Company

INDUSTRY

collaborator

Cancer Research UK

OTHER

lead

University College, London

OTHER